The research team, led by Sithum Munasinghe with colleagues including Kate McBride, Phuong Dung Nguyen, Matthew Spittal and Andrew Page, focused on nine cancer types previously linked to rising rates in younger adults: breast, colorectal, uterine, kidney, liver, pancreatic, thyroid, prostate and oesophageal cancers. To interpret those trends, they compared them against three comparator cancers without early-onset increases: lung cancer, cervical cancer and melanoma of the skin. The design matters because it separates genuine generational risk changes from artefacts of improved detection, which have complicated the debate over why young people appear to be developing certain cancers at higher rates than their parents and grandparents did.

Age-period-cohort analysis is a statistical framework designed to disentangle three forces that all shape disease rates over time. Age effects capture the well-known rise in cancer risk as people get older. Period effects reflect influences that affect everyone alive at a particular moment, such as the introduction of a national screening programme, a change in diagnostic practice or a new treatment that alters recorded mortality. Cohort effects, by contrast, track the experiences of people born in the same era who carry shared exposures through life, from dietary patterns and physical activity levels to antibiotic use, obesity prevalence and early-life microbiome changes. Because the three dimensions are mathematically interdependent, with each year of birth equal to a calendar year minus an age, sophisticated modelling is required to estimate each component without confounding the others.

When the researchers applied this framework to incidence data, a clear pattern emerged. For both males and females, there were increasing cohort effects in colorectal, liver, pancreatic and thyroid cancers, meaning that successive birth cohorts experienced higher rates of these cancers at equivalent ages than earlier generations did. Among women, uterine cancer showed the same generational rise, and among men, prostate cancer did as well. The steepest relative increases were recorded for pancreatic cancer in females and thyroid cancer in males, two sites that have featured prominently in international reports of early-onset cancer concern. These increases were evident after accounting for age and calendar-period influences, strengthening the interpretation that something about the lived experience of later-born generations is driving the trend.

Equally informative were the cancers that bucked the pattern. Cohort effects were decreasing for melanoma of the skin and for cervical cancer among women, a finding consistent with successful public health interventions: sun-protection campaigns that have reshaped behaviour since childhood for Australians born after the 1970s, and human papillomavirus vaccination and cervical screening that have driven down rates in younger cohorts. For lung cancer and oesophageal cancer, the analysis found no substantial differences across birth cohorts, suggesting that the early-onset increases reported for other cancer types are not a universal phenomenon but a site-specific one tied to particular exposures.

The period effects told a different and largely reassuring story. Once cohort effects were accounted for, period influences on incidence were relatively stable for most cancer types, with the exceptions of prostate cancer among men and cervical cancer among women. Stable period effects suggest that calendar-specific events, such as the gradual rollout of diagnostic technologies, have not been the dominant driver of the observed incidence trends for most of these cancers. This is a crucial point for the ongoing scientific debate, because critics of the early-onset cancer narrative have argued that increased screening and incidental detection could explain much of the apparent rise. The Australian data indicate that for the majority of the cancers studied, the generational signal, not the calendar signal, carries the weight.

Mortality trends painted a more optimistic picture overall. Decreasing period and cohort effects for cancer mortality were evident for most cancer types and for both males and females, reflecting decades of progress in early detection, surgical technique, systemic therapies and supportive care. However, the exceptions were notable: increasing period effects were observed for thyroid cancer and pancreatic cancer, and for cervical and uterine cancers among women. Rising period effects in mortality can reflect shifts in the underlying burden of disease arriving at the health system, or changes in how deaths are certified and classified, and for pancreatic cancer in particular they align with a cancer type that remains notoriously difficult to detect early and treat effectively.

The authors conclude that the higher population-level incidence of these cancer types among later-born cohorts may indicate cohort-specific differences in risk factors associated with these outcomes. That phrasing is deliberately cautious, and appropriately so. Age-period-cohort models are descriptive-analytic tools: they can establish that a generational pattern exists and quantify its magnitude, but they cannot identify which specific exposures caused it. Candidate explanations discussed in the broader literature include rising obesity rates, changes in diet and alcohol consumption, altered gut microbiota, earlier puberty, sedentary lifestyles and antibiotic exposure in early life, but the present study does not test these hypotheses directly. What it does provide is a rigorous temporal scaffold onto which future aetiological research can be mapped.

The Australian setting gives the findings particular weight. The country maintains comprehensive, population-based cancer registries with incidence data reaching back to 1982 and mortality data to 1971, allowing cohort comparisons that span people born across most of the twentieth century. Australia also offers instructive natural experiments in cancer control, from its world-leading sun-safety campaigns to its organised cervical screening and HPV vaccination programmes, and the decreasing cohort effects for melanoma and cervical cancer show those interventions registering clearly in the generational data. The contrast between these success stories and the rising cohort effects for colorectal, pancreatic, liver and thyroid cancers underscores that the early-onset phenomenon is not an inevitable feature of modern life but a modifiable one.

For clinicians and policymakers, the implications are twofold. First, health systems may need to reconsider age thresholds for awareness and, where evidence supports it, screening for cancers increasingly seen in younger adults, since guidelines historically calibrated to older populations can leave early-onset cases detected late. Second, prevention strategies must target exposures accumulated from childhood onward, because cohort effects by definition reflect risks carried across the life course rather than hazards encountered in middle age. The study used aggregate, publicly available tabulations of incidence and mortality data and required no individual-level ethics approval, and the authors declared no competing interests. As cohorts born in the 1980s and 1990s move further into middle age, continued surveillance will reveal whether the generational risk elevations documented here persist, plateau or, with effective intervention, follow the downward path already traced by melanoma and cervical cancer in the same population.

Subject of Research: Age-period-cohort analysis of early-onset cancer incidence and mortality trends in Australia

Article Title: Age, period, and cohort effects in the population-level incidence and mortality of cancer types associated with early onset increases in Australia

Article References: Munasinghe, S., McBride, K., Nguyen, P. D., Spittal, M., & Page, A. (2026). Age, period, and cohort effects in the population-level incidence and mortality of cancer types associated with early onset increases in Australia. BMC Medicine. https://doi.org/10.1186/s12916-026-05293-x

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05293-x

Keywords: early-onset cancer, age-period-cohort analysis, cancer epidemiology, Australia, incidence trends, mortality trends, colorectal cancer, pancreatic cancer, thyroid cancer, birth cohort effects, BMC Medicine, cancer prevention

The team set out to quantify, systematically and at genome-wide scale, how well the two dominant study designs converge. Cross-sectional designs compare genetic associations between individuals of different ages at a single time point, asking whether a variant’s effect differs between a 45-year-old and a 65-year-old sampled simultaneously. Longitudinal designs instead track the same individuals over time, modeling within-person change directly. In principle, if aging is the only force at work, both approaches should estimate the same quantity. In practice, they rest on strong assumptions: that genetic effects do not vary by birth cohort, that sampling is comparable, and that participation in the study does not itself depend on age and phenotype.

Using the UK Biobank, the researchers analyzed 31 non-binary health-related phenotypes spanning cognition, physiology, clinical indicators, anthropometrics and lifestyle behaviors. The cross-sectional arm drew on up to 498,845 participants aged 40 to 69 at baseline; the longitudinal arm followed up to 99,459 of them across repeat assessments conducted between 2012 and 2024, with a mean follow-up of roughly 11 years. At the phenotypic level, cross-sectional age effects explained about 70.6 percent of the variance in longitudinal estimates—substantial, but far from the near-perfect agreement that equivalence would demand. The largest discrepancies appeared in behavioral traits. For the number of medications taken, the cross-sectional model estimated an age effect three times larger than the longitudinal one. For smoking and alcohol use, the two designs even disagreed about the sign: traits that decline with age within individuals falsely appeared to increase with age when compared across individuals.

The culprit, the authors show, is confounding by birth cohort. In cross-sectional data, age and year of birth are almost perfectly inversely correlated—age equals period minus cohort—so differences between generations can masquerade as aging. Because date of birth and cross-sectional age correlated at roughly −0.99 in the UK Biobank, negative cohort effects systematically inflate cross-sectional age estimates and can even reverse their direction. Significant cohort effects emerged for 28 of the 31 traits, and cohort confounding accounted for a striking 90.8 percent of the variance in the discrepancy between longitudinal and cross-sectional age estimates. The historical and social contexts in which people were born—educational reforms, economic upheavals, public health policies such as the 1965 UK ban on cigarette advertising—leave lasting marks on trait levels that a cross-sectional comparison misreads as aging.

The researchers then turned to the genetic level, implementing a two-step genome-wide strategy that combined scans for marginal genetic effects, cross-sectional gene-by-age interactions and genetic effects on longitudinal change. They identified 57 linkage-disequilibrium-independent variants with significant age-varying effects, most of them detected in cross-sectional analyses (44 variants, in up to 406,226 individuals) and fewer in longitudinal analyses (14 variants, in up to 83,579 individuals). The variants clustered around anthropometric traits such as weight, body fat-free mass and body mass index, metabolic indicators such as basal metabolic rate, and clinical outcomes including medication count and number of cancers. Self-reported health behaviors—physical activity, smoking, sleep—showed few or no significant age-varying genetic effects.

Encouragingly, direction was largely preserved across designs: 84.21 percent of the 57 variants showed consistent interaction directions whether tested cross-sectionally or longitudinally. Among the concordant variants, both attenuation and intensification of genetic effects with age were common, accounting for 50 percent and 35.42 percent of cases respectively. The pattern was trait-specific. Genetic effects on obesogenic traits tended to weaken with age, consistent with earlier reports of declining heritability for body mass index and depression in adulthood—plausibly because accumulated environmental exposures, medication, dietary change and shifting occupational circumstances gradually swamp genetic predisposition. Conversely, traits adversely affected by aging itself, such as cancer count, medication burden and reaction time, more often showed intensifying genetic influence over time. Crossover effects, in which the direction of a genetic association reverses across the lifespan, were rare, appearing in just seven variants with no detectable marginal effect.

Magnitude was another matter. Although cross-sectional and longitudinal estimates of age-varying genetic effects were linearly related, the regression slope was significantly below one, indicating that cross-sectional estimates were systematically larger. Decomposing the discrepancies revealed a familiar hierarchy: gene-by-birth-year interactions explained 70.8 percent of the variance in effect-size differences across variants, selective participation accounted for an additional 11.6 percent, and unmodeled nonlinear age trajectories contributed only 4.2 percent. For several variants—including rs2597355 on depression, rs56299829 on fruit intake and rs17362578 on walking pace—cohort confounding was strong enough to reverse the estimated direction of the age-varying genetic effect under a cross-sectional model. Suggestive gene-by-cohort effects were observed for 10 of the 57 variants, and the authors note that such effects are not mere noise: they capture how societal change reshapes genetic associations across generations, as documented in studies of genetic influences on social outcomes before and after the collapse of the Soviet Union and in response to educational policy reforms.

Participation bias, the second-largest contributor, operates differently in each design. Cross-sectional estimates are vulnerable to selective volunteering at baseline—the UK Biobank’s well-documented healthy volunteer effect—whereas longitudinal models adjust for time-invariant selection but assume that continued participation is independent of changes in phenotype. Because the pressures shaping initial recruitment differ from those governing retention, the two designs absorb different slices of selection bias. The scale of loss to follow-up is considerable: of the 399,661 baseline participants who did not take part in follow-up research, 42,001—about 11 percent—died before the first longitudinal assessment, though most attrition stemmed from other causes. Reweighting the samples to improve representativeness shifted cross-sectional estimates more than longitudinal ones, with sign reversals observed for four traits, and sample representativeness explained 2.8 percent of the discrepancy between designs—small next to the 90.8 percent attributable to cohort effects at the phenotypic level.

Nonlinear aging, by contrast, proved a minor player. Significant quadratic age effects were detected for 17 traits, meaning some aging trajectories genuinely bend rather than run straight, and such curvature can make estimated slopes depend on the age range sampled—the cross-sectional sample tops out at 69 years of baseline age while follow-up reaches 86. Yet deviations from linearity explained under 5 percent of the variance in design discrepancies, and the authors caution that their small-subset estimates are diluted by measurement error, with a dilution ratio of −0.43 for the nonlinear component. The findings replicated at the polygenic level: polygenic score effects on anthropometric and metabolic traits showed consistent directions but divergent magnitudes across designs, with cohort confounding again dominant at 85.2 percent of explained variance—a result with practical implications for anyone deploying polygenic risk scores across age groups or generations.

Where does this leave the field? The authors argue that neither design is immune to its own pathologies, and that robust inference demands integrating both. Cross-sectional analyses offer unmatched statistical power and age range, maximizing discovery of candidate age-varying variants; longitudinal analyses provide direct modeling of within-person change, control against time-invariant confounding and the ability to detect gene-by-cohort effects and nonlinear trajectories that cross-sectional data cannot in principle deliver. The team also illustrates how longitudinally derived genetic instruments could feed into Mendelian randomization, recovering the well-established adverse effect of body mass index on systolic blood pressure, albeit with wide uncertainty given the scarcity of strong instruments for change. As prospective biobanks, electronic health records and whole-genome sequencing expand, the framework will extend to rare variants and richer repeated measures. For now, the message is clear: before declaring that a gene’s influence grows or fades with age, researchers must ask whether they are measuring aging—or merely the echo of the century in which their participants were born.

Subject of Research: Age-varying genetic effects on complex traits and how study design, cohort confounding and participation bias shape their inference

Article Title: Design and model choices shape inference of age-varying genetic effects on complex traits

Article References: Schoeler, T., Wiegrebe, S., Winkler, T. W., & Kutalik, Z. (2026). Design and model choices shape inference of age-varying genetic effects on complex traits. Nature Aging. https://doi.org/10.1038/s43587-026-01232-w

Image Credits: AI Generated

DOI: 10.1038/s43587-026-01232-w

Keywords: genetic epidemiology, age-varying genetic effects, UK Biobank, birth cohort effects, participation bias, genome-wide association study, gene-by-age interaction, longitudinal analysis, cross-sectional design, polygenic scores, Mendelian randomization, complex traits

The research team, led by Anna L.V. Johansson of the Karolinska Institutet and Søren Friis and Mats Lambe and colleagues across the Nordic cancer research community, analysed more than 2.2 million cancer cases diagnosed between 2003 and 2022 across 18 major cancer sites. They compared incidence trends in adults aged 20 to 49 with those aged 50 to 84, and extended some analyses back to 1978 to probe for birth-cohort effects, the statistical fingerprints left behind when entire generations carry elevated risk through life. The Nordic registries are legally mandated, near-complete, and histologically verified in 92 to 97 percent of cases, making the region an unusually clean laboratory for spotting genuine epidemiological signals rather than artefacts of sloppy record-keeping.

The headline finding is stark: early-onset cancer incidence increased for 12 of the 18 cancer sites examined over the two-decade study window. The steepest rises, with estimated annual percent changes of at least 2 percent, occurred in thyroid, colon, kidney cancers, and melanoma. Rates also climbed, more modestly, for rectal, prostate, liver, and corpus uteri cancers as well as multiple myeloma, with smaller increases for cervical, pancreatic, and breast cancers. Only lung and ovarian cancer showed significant declines among the young, a pattern the authors partly attribute to falling smoking prevalence and changing use of hormonal contraceptives.

What makes the study particularly striking is the age gradient buried within the early-onset group. When the researchers stratified patients into five-year age bands, they found that the largest increases for colon, pancreatic, breast, and kidney cancers occurred in adults under 35, while melanoma, thyroid, rectal, liver, and corpus uteri cancers rose fastest in the 35 to 49 bracket. In other words, for several major malignancies, the youngest adults, those in their twenties and early thirties, are experiencing the sharpest acceleration, a pattern that cannot be explained away by screening programmes, which typically target people over 50.

The birth-cohort analysis adds a further layer of concern. Successive generations born from roughly the 1960s onward have carried progressively higher rates of colon cancer, and for rectal, pancreatic, breast, kidney, thyroid cancers, and melanoma, the elevation begins with cohorts born from the late 1970s and 1980s. This generational pattern suggests that exposures acting early in life, in childhood, adolescence, or young adulthood, may be programming elevated cancer risk decades before diagnosis. It also implies that today’s young adults may carry their excess risk into older age, when cancer becomes more common overall, potentially compounding the future disease burden.

Not every trend moved in the same direction across the region. In the four largest countries, Denmark, Finland, Norway, and Sweden, trends for melanoma, colon, rectal, breast, kidney, and thyroid cancers were broadly consistent, but patterns in Iceland, the Faroe Islands, and Greenland were more variable, particularly for melanoma. Sweden stood alone with a rising rate of early-onset pancreatic cancer. Intriguingly, for rectal, prostate, corpus uteri, and cervical cancers, incidence rose exclusively among the young while simultaneously falling among older adults, a divergence that hints at genuinely shifting risk landscapes rather than uniform changes in detection.

So what is driving the rise? The authors are careful to note that the mechanisms are likely multifactorial and vary by cancer type, and that a descriptive registry study cannot assign causation. Obesity is a leading suspect: seven of the nine obesity-related cancer sites defined by the World Health Organization, including colon, rectum, liver, pancreas, corpus uteri, kidney, and thyroid, showed increasing early-onset incidence in the Nordic data. Yet the pattern was inconsistent with the known strength of obesity-cancer associations, suggesting excess body weight alone cannot explain the trends. Related exposures, sedentary lifestyles, shifting dietary patterns high in fat, sugar, and red meat and low in fibre, alcohol, ultraviolet radiation, reproductive changes such as fewer births and later first pregnancies, and genetic predisposition, all remain on the table. Notably, smoking and alcohol consumption have declined among young Nordics, which may be masking even larger increases driven by other factors.

Increased diagnostic scrutiny complicates the picture further. The widespread adoption of ultrasound, computed tomography, and magnetic resonance imaging has lowered the threshold for detecting small tumours, and the dramatic global rise in thyroid cancer is widely attributed at least in part to this diagnostic intensity. Similarly, rising early-onset prostate cancer rates likely reflect opportunistic prostate-specific antigen testing in men under 50, despite the absence of formal screening recommendations. For melanoma, more aggressive biopsying of pigmented lesions may contribute, although the authors also point to an encouraging counter-trend: early-onset melanoma incidence declined in the most recent decade, possibly reflecting the success of sun-protection campaigns and restrictions on tanning salons introduced across the Nordic countries in the 2000s.

Some researchers have proposed a more provocative framework: accelerated biological ageing. Recent generations may accumulate lifestyle and environmental exposures that make their biological age outpace their chronological age, and advanced biological age has been linked to elevated overall cancer risk as well as lung and colorectal cancer in large biobank studies. The hypothesis is attractive because biological ageing is potentially modifiable, opening avenues for primary prevention, but the authors stress that individual-level data on risk factor histories will be needed to test it properly in the Nordic context.

The absolute numbers remain modest. Between the first and last five-year periods of the study, early-onset cases across the 18 sites rose by 9,174, from 47,491 to 56,665, compared with an increase of more than 145,000 cases among older adults. Melanoma accounted for the largest absolute jump in the young, with 2,918 additional cases, followed by thyroid, breast, colon, and kidney cancers. But the authors argue the trajectory matters more than the tally. Young patients face decades of survivorship, potential long-term treatment sequelae, and productivity losses, and healthcare systems will need resources tailored specifically to younger cancer patients. The study’s central message is a call to action: intensify research into modifiable early-life risk factors, strengthen primary prevention starting in childhood and adolescence, and raise clinical awareness of malignancies in a population not traditionally perceived as being at risk.

Subject of Research: Population-based trends in early-onset cancer incidence across seven Nordic countries from 2003 to 2022

Article Title: Trends in early-onset cancer incidence rates in the Nordic countries (2003–2022): a population-based study

Article References: Johansson, A. L., Kønig, S. M., Cardoso, R., Møller, H., Ursin, G., Skog, A., Persson, Å., Birgisson, H., Kristjánsdóttir, L., Tanskanen, T., Dahl-Olsen, E. D., Bray, F., Friis, S., & Lambe, M. (2026). Trends in early-onset cancer incidence rates in the Nordic countries (2003–2022): a population-based study. The Lancet Regional Health – Europe, 70, Article 101858. https://doi.org/10.1016/j.lanepe.2026.101858

Image Credits: AI Generated

DOI: 10.1016/j.lanepe.2026.101858

Keywords: early-onset cancer, Nordic countries, cancer incidence, thyroid cancer, colorectal cancer, birth cohort effects, obesity-related cancers, melanoma, NORDCAN, cancer epidemiology, cancer prevention, young adults